Business
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial cl...
About this update from Bolt Metals Corp.
[{"type":"text","content":"Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update\nFirst-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “We are encouraged by what we have seen thus far in patients treated with BDC-4182, a next-generation Boltbody™ ISAC. BDC-4182 has a unique mechanism of action that has the potential to combine the power of ADCs with the durability of T-cell engagers and unlock a new frontier in cancer treatment,” said Willie Quinn, President and Chief Executive Officer. “We continue to enroll patients with gastric and gastroesophageal cancer in our ongoing clinical trial, and we look forward to reporting initial data in the third quarter of 2026.” Recent Highlights and Anticipated Milestones Initial clinical data from BDC-4182 Phase 1/2 study for patients with gastric and gastroesophageal cancer expected in the third quarter of 2026. BDC-4182 is a next-generation Boltbody™ ISAC targeting claudin 18.2, a clinically validated target with expression in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and other tumor types. In preclinical models, including cancer models with low claudin 18.2 expression, BDC-4182 demonstrated significant anti-tumor activity, induced immunological memory, and outperformed cytotoxic ADCs. Bolt has implemented step-up dosing, which has been successfully used commercially for T-cell engagers, as a strategy to get to higher doses safely. The clinical trial in gastric and gastroesophageal cancers is ongoing, and the Company expects to present initial clinical data in the third quarter of 2026.Next-generation Boltbody™ ISACs targeting CEA and PD-L1. Two additional ISAC programs in Bolt’s pipeline are currently on hold. Once BDC-418...